HCPCS code Q5110: Nivestym, per 1 mcg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What Q5110 covers

Q5110 identifies Nivestym (filgrastim-aafi), a biosimilar granulocyte colony-stimulating factor. Oncology practices commonly use filgrastim products to reduce infection risk from neutropenia associated with cancer treatment. Filgrastim is also used in settings such as bone marrow transplantation and stem-cell mobilization. It is administered by subcutaneous injection or intravenous infusion, depending on clinical use. Q5110 identifies the drug, not the administration service.

CMS assigns Q5110 to the Part B drug pricing method; when Medicare covers it, payment generally uses CMS’s quarterly Average Sales Price drug pricing files. Its physician fee schedule status is E, meaning CMS excludes it from the physician fee schedule and, when covered, pays under another method. CMS also assigns special Medicare coverage instructions to this code. One unit represents 1 microgram of filgrastim-aafi, so reported units correspond to the total microgram dose furnished.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where Q5110 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

Q5110 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the Q5110 rate is calculated

Each of Q5110’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for Q5110

Q5110 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

Q5110 compared with similar codes

How to choose

Q5101Zarxio injectionPer 1 mcg

Q5101 is for filgrastim-sndz (Zarxio); Q5110 is for filgrastim-aafi (Nivestym). Select the code for the specific product administered.

Q5125Releuko injectionPer 1 mcg

Q5125 identifies filgrastim-ayow (Releuko), not Nivestym. Both are filgrastim biosimilars, but each product has its own code.

Q5111Udenyca injectionPer 0.5 mg

Q5111 is for pegfilgrastim-cbqv (Udenyca), a longer-acting pegfilgrastim product. Q5110 is for filgrastim-aafi (Nivestym), reported per microgram.

Codes related to Q5110

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates